RALEIGH, N.C., Nov. 8, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Tuesday, November 15, at 1:30 PM Eastern Time at the Lotte New York Palace Hotel in New York City.
Dr. Sirgo will discuss strategic initiatives supporting BUNAVAIL ® (buprenorphine and naloxone) buccal film (CIII) and the launch of BELBUCA ® (buprenorphine) buccal film (CIII) by BDSI's commercial partner, Endo Pharmaceuticals. Also covered will be an update on the development of Clonidine Topical Gel for painful diabetic neuropathy and the buprenorphine 30-day injection for opioid dependence and chronic pain. The presentation will be webcast live and can be accessed at www.bdsi.com. For those who are not available to listen to the live broadcast, replay of the webcast will be available on the BDSI website. About BioDelivery Sciences International BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's development strategy focuses on the utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.